n this study, 773 untreated breast cancer patients from all over China were collected and followed up for at least 5 years. We obtained clinical data from 773 cases, RNA sequencing data from 752 cases ...

CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...

A new tool provides a personalised risk score for developing breast cancer, and can reduce unnecessary investigations.

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to ...

Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...

An image-only artificial intelligence (AI) model for predicting the five-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to ...